This photo provided by McDonald's shows the McPlant burger. McDonald’s will begin selling a vegan burger in the United Kingdom and Ireland this month. The McPlant burger, developed with Beyond Meat, features a plant-based patty on a vegan sesame bun with vegan cheese, vegan sauce and other toppings. Both the patty and the cheese are made with pea protein.(McDonald's via AP)
McDonald’s will begin selling a vegan burger in the United Kingdom and Ireland this month.
The McPlant burger, developed with Beyond Meat, features a plant-based patty on a vegan sesame bun with vegan cheese, vegan sauce and other toppings. Both the patty and cheese are made with pea protein.
The McPlant will be cooked separately from other McDonald’s sandwiches with dedicated utensils. It will go on sale in 10 restaurants this month before being rolled out to 250 more later this fall. The McPlant will be sold in all McDonald's in the U.K. and Ireland in 2022.
The Chicago-based burger giant said Thursday that vegan burgers have appeared on menus in some of its regions before. But this is the first time a vegan burger __ accredited by the Vegetarian Society __ will be sold by McDonald’s in the U.K. and Ireland.
The company said it decided to make the McPlant vegan to meet customer expectations in the U.K. and Ireland. It has not said when the McPlant will go on sale in the U.S.
McDonald’s announced its partnership with El Segundo, California-based Beyond Meat in February. It has also tested the McPlant burger in Denmark, Sweden and Austria, but in all of those markets, McDonald’s used regular cheese and mayonnaise, so the sandwich wasn’t vegan.7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022
One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.
But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.
There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.
However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that
are ready to make strong moves forward in 2022.View the "7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022"